GN and Demant lose VA market shares again April marked the fifth month in a row that GN has lost market shares on US public sales channel Veterans Affairs. Demant's share has shrunk for the second consecutive month. Photo: GN Store Nord / PR BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT Published: 02.06.21 at 14:24 Both GN Hearing and Demant lost shares in the Veteran Affairs (VA) sales channel to competitors in April. This was revealed in the delayed monthly report published by the public sales channel, DNB analyst Rune Majlund Dahl tells Ritzau Finans. Already a subscriber? Log in. Read the whole article Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial. Access all locked articles Receive our daily newsletters Access our app First name: Last name: E-mail address: Password: I accept the terms and conditions An error has occured. Please try again later. Create trial Get full access for you and your coworkers. Start a free company trial today More from MedWatch WS Audiology brings in head of EMEA region from Coloplast The hearing aid manufacturer has appointed Coloplast’s now outgoing president for emerging markets as president for the EMEA region. Dupixent could dominate pediatric eczema market for up to a decade, analysis finds Sanofi and Regeneron will be able to call themselves market leaders within atopic eczema treatment for children aged 6 months to 5 for years to come, according to Globaldata. FDA advisors support approval for Ferring's intestinal infection medicine All signs indicate that Ferring Pharmaceuticals is on the cusp of being market authorized for its biologic candidate against C. difficile infection. Pharmacosmos expects massive growth in four years The company’s new chief executive has ambitions of reaching a DKK 2.5bn (USD 325m) revenue within the time frame. The Lundbeck Foundation, ATP, LEGO asset manager join forces on secretive project Three of Denmark’s biggest funds have come together for a yet unknown project, which includes the establishment of three new firms. Print Print Increase text size Increase text size Decrease text size Decrease text size Further reading Eli Lilly's Mounjaro could become one of the world's biggest drugs ever Novo Nordisk faces potential impact of new US legislation Dupixent could dominate pediatric eczema market for up to a decade, analysis finds Novo Nordisk brings forward salary regulations for 50,000 employees due to increasing inflation WS Audiology brings in head of EMEA region from Coloplast Related articles Swiss hearing aid giant comes out on top after covid-19 crisis WSA wants Widex products back in US sales channel GN flagship product gets off to a bad start with war veterans: "It is an unfortunate cocktail"